Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus conference.
作者信息
Burak Kelly W, Thomas Melanie B, Zhu Andrew X
机构信息
Liver Unit, Division of Gastroenterology, Department of Medicine, University of Calgary, Calgary, Canada.
出版信息
HPB (Oxford). 2010 Jun;12(5):321-2. doi: 10.1111/j.1477-2574.2010.00186.x.
Abstract
摘要
相似文献
1
Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus conference.
HPB (Oxford). 2010 Jun;12(5):321-2. doi: 10.1111/j.1477-2574.2010.00186.x.
2
Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus statement.
HPB (Oxford). 2010 Jun;12(5):313-20. doi: 10.1111/j.1477-2574.2010.00183.x.
3
Major achievements in hepatocellular carcinoma.
Lancet. 2009 Feb 21;373(9664):614-6. doi: 10.1016/S0140-6736(09)60381-0.
4
Review article: the management of hepatocellular carcinoma.
Aliment Pharmacol Ther. 2010 Feb 15;31(4):461-76. doi: 10.1111/j.1365-2036.2009.04200.x. Epub 2009 Nov 19.
5
Sorafenib, doesn't it have any competitor in advanced hepatocellular carcinoma?
J Gastroenterol Hepatol. 2011 Nov;26(11):1585-6. doi: 10.1111/j.1440-1746.2011.06901.x.
6
Safety of transarterial chemoembolization plus sorafenib combination treatment in unresectable hepatocellular carcinoma.
Scand J Gastroenterol. 2010 Apr;45(4):511-2. doi: 10.3109/00365521003628335.
7
Sorafenib in combination with transarterial chemoembolization for the treatment of hepatocellular carcinoma.
Clin Adv Hematol Oncol. 2016 Aug;14(8):585-7.
8
Current management of hepatocellular carcinoma.
Med Clin North Am. 2009 Jul;93(4):885-900, viii. doi: 10.1016/j.mcna.2009.03.004.
9
Contemporary management of hepatocellular carcinoma.
Clin Med (Lond). 2008 Aug;8(4):442-7. doi: 10.7861/clinmedicine.8-4-442.
10
Targeted therapies: Role of sorafenib in HCC patients with compromised liver function.
Nat Rev Clin Oncol. 2009 Sep;6(9):505-6. doi: 10.1038/nrclinonc.2009.114.
本文引用的文献
1
Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus statement.
HPB (Oxford). 2010 Jun;12(5):313-20. doi: 10.1111/j.1477-2574.2010.00183.x.
2
Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study.
Cardiovasc Intervent Radiol. 2010 Feb;33(1):41-52. doi: 10.1007/s00270-009-9711-7. Epub 2009 Nov 12.
3
Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes.
Gastroenterology. 2010 Jan;138(1):52-64. doi: 10.1053/j.gastro.2009.09.006. Epub 2009 Sep 18.
4
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Lancet Oncol. 2009 Jan;10(1):25-34. doi: 10.1016/S1470-2045(08)70285-7. Epub 2008 Dec 16.
5
Sorafenib in advanced hepatocellular carcinoma.
N Engl J Med. 2008 Jul 24;359(4):378-90. doi: 10.1056/NEJMoa0708857.
6
Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis.
Hepatology. 2008 Jan;47(1):71-81. doi: 10.1002/hep.21980.
7
Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics.
J Hepatol. 2007 Mar;46(3):474-81. doi: 10.1016/j.jhep.2006.10.020. Epub 2006 Nov 29.
8
Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies.
Cardiovasc Intervent Radiol. 2007 Jan-Feb;30(1):6-25. doi: 10.1007/s00270-006-0062-3.
9
Safety and efficacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis.
J Vasc Interv Radiol. 2005 Dec;16(12):1653-9. doi: 10.1097/01.RVI.0000182185.47500.7A.
10
Management of hepatocellular carcinoma.
Hepatology. 2005 Nov;42(5):1208-36. doi: 10.1002/hep.20933.
Zotero 插件